0904 Rain
BioCentury & Getty Images

Product Development

Rain to advance growing precision oncology pipeline with $63M series B

Sep 4, 2020 | 11:44 PM GMT

A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo — through clinical proof of concept. 

Boxer Capital led Thursday’s

Read the full 641 word article

How to gain access

Continue reading with a
two-week free trial.